Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Daniel Prieto-Alhambra has been awarded the 'Special ISPE award for contributions to public health associated with the COVID-19 pandemic.'

Dani receiving his award from ISPE
Dani (second from right) with his ISPE award recognising his contribution to COVID-19 research

The award was presented at the 38th International Conference on Pharmacoepidemiology, which took place in Copenhagen, in recognition of Dani's demonstrable impact on public health related to the COVID-19 pandemic through his work in Pharmacoepidemiology.

Daniel is the Professor of Pharmaco- and Device Epidemiology and Section Head for Health Data Sciences at the Botnar Research Centre, NDORMS, University of Oxford.

As a member of the European Health Data & Evidence Network (EHDEN) and the Observational Health Data Sciences and Informatics (OHDSI), Dani has studied the impacts and effects of COVID-19 throughout the pandemic to better inform the global response.

Projects included:

  • Projects exploring the risks and efficacy of the COVID-19 vaccines, including the impact on neurological disorders;
  • An international study to understand the characteristics of patients suffering from COVID-19 in greater detail;
  • Research to understand the safety profile and risks of Hydroxychloroquine, that was considered a potential COVID-19 treatment;
  • And hosting a COVID-19 virtual study-a-thon to inform healthcare decision-making in response to the global pandemic.

Commenting on the award Daniel said: "All senior awards recognise the work of many, not one individual. This one in particular acknowledges the work of my team at the Botnar Research Centre (University of Oxford), Erasmus MC Rotterdam, and colleagues in the EHDEN and OHDSI communities who went the extra mile for months. We rallied to generate actionable evidence on the impact of COVID-19, and for the monitoring of COVID vaccine safety."

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.